

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
S1803	Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)	Therapy	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Janssen 54767414MM Y3021	AURIGA: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com